No headlines found.
Globe Newswire (Thu, 19-Mar 8:00 AM ET)
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globe Newswire (Tue, 17-Feb 8:00 AM ET)
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Chemomab Therapeutics Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol CMMB.
As of April 22, 2026, CMMB stock price climbed to $1.69 with 10,260 million shares trading.
CMMB has a beta of 1.24, meaning it tends to be more sensitive to market movements. CMMB has a correlation of 0.10 to the broad based SPY ETF.
CMMB has a market cap of $12.17 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CMMB traded as high as $10.20 and as low as $1.35.
CMMB has underperformed the market in the last year with a price return of -63.6% while the SPY ETF gained +39.8%. CMMB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.7% and +0.6%, respectively, while the SPY returned +4.0% and +7.9%, respectively.
CMMB support price is $1.57 and resistance is $1.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMMB shares will trade within this expected range on the day.
